These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28891448)

  • 1. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selexipag: A Review in Pulmonary Arterial Hypertension.
    Duggan ST; Keam SJ; Burness CB
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selexipag for the treatment of pulmonary arterial hypertension.
    Sharma K
    Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selexipag: First Global Approval.
    Scott LJ
    Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of selexipag for the treatment of pulmonary hypertension.
    Panagiotidou E; Boutou A; Pitsiou G
    Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
    Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
    J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selexipag for the treatment of pulmonary arterial hypertension.
    Genecand L; Wacker J; Beghetti M; Lador F
    Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selexipag for the treatment of pulmonary arterial hypertension.
    Skoro-Sajer N; Lang IM
    Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
    Kuwano K; Kosugi K; Fuchikami C; Funaki S
    Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.